About Inovio Pharmaceuticals
Inovio Pharmaceuticals is a company based in Plymouth Meeting (United States) founded in 1983 by Joseph Kim.. The company has 134 employees as of December 31, 2024. Inovio Pharmaceuticals has completed 2 acquisitions, including Bioject and VGX Pharmaceuticals. Inovio Pharmaceuticals offers products and services including DNA Medicines and CELLECTRA Devices. Inovio Pharmaceuticals operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Regeneron Pharmaceuticals and MorphoSys, among others.
- Headquarter Plymouth Meeting, United States
- Employees 134 as on 31 Dec, 2024
- Founders Joseph Kim
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Inovio Pharmaceuticals, Inc.
-
Annual Revenue
$217.76 K-73.83as on Dec 31, 2024
-
Net Profit
$-107.25 M20.62as on Dec 31, 2024
-
EBITDA
$-110.87 M15.83as on Dec 31, 2024
-
Latest Funding Round
$37.6 M (USD), Grant
Dec 16, 2020
-
Investors
NIH
& 8 more
-
Employee Count
134
as on Dec 31, 2024
-
Investments & Acquisitions
Bioject
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Inovio Pharmaceuticals
Inovio Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol INO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Inovio Pharmaceuticals
Inovio Pharmaceuticals offers a comprehensive portfolio of products and services, including DNA Medicines and CELLECTRA Devices. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Plasmids that enable cells to produce proteins against diseases
Devices for delivering DNA plasmids into cells effectively
Unlock access to complete
Unlock access to complete
Funding Insights of Inovio Pharmaceuticals
- Total Funding Total Funding
- Total Rounds 31
- Last Round Grant — $37.6M
-
First Round
First Round
(07 Jun 2002)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2020 | Amount | Grant - Inovio Pharmaceuticals | Valuation |
investors |
|
| Jun, 2020 | Amount | Grant - Inovio Pharmaceuticals | Valuation |
investors |
|
| Apr, 2020 | Amount | Grant - Inovio Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Inovio Pharmaceuticals
Inovio Pharmaceuticals has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Korea Investment Holdings and Gates Foundation. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are targeted by this private equity firm.
|
Founded Year | Domain | Location | |
|
Investment holding firm established in Seoul in 2003.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Inovio Pharmaceuticals
Inovio Pharmaceuticals has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Bioject and VGX Pharmaceuticals. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
DNA-based vaccines for infectious diseases and cancers are developed.
|
2002 | ||||
|
Needle-free injection therapies are developed for medical drug delivery.
|
1985 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Inovio Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Inovio Pharmaceuticals Comparisons
Competitors of Inovio Pharmaceuticals
Inovio Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Regeneron Pharmaceuticals and MorphoSys, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Inovio Pharmaceuticals
Frequently Asked Questions about Inovio Pharmaceuticals
When was Inovio Pharmaceuticals founded?
Inovio Pharmaceuticals was founded in 1983 and raised its 1st funding round 19 years after it was founded.
Where is Inovio Pharmaceuticals located?
Inovio Pharmaceuticals is headquartered in Plymouth Meeting, United States. It is registered at Plymouth Meeting, Pennsylvania, United States.
Who is the current CEO of Inovio Pharmaceuticals?
Joseph Kim is the current CEO of Inovio Pharmaceuticals. They have also founded this company.
How many employees does Inovio Pharmaceuticals have?
As of Dec 31, 2024, the latest employee count at Inovio Pharmaceuticals is 134.
What is the annual revenue of Inovio Pharmaceuticals?
Annual revenue of Inovio Pharmaceuticals is $217.76K as on Dec 31, 2024.
What does Inovio Pharmaceuticals do?
Founded in 1983 and based in Plymouth Meeting, United States, Inovio Pharmaceuticals operates in the biotechnology sector. Synthetic DNA vaccines are developed, delivered via proprietary electroporation to elicit antibody and T-cell responses. The pipeline encompasses immunotherapies targeting cancers of the cervix, head and neck, prostate, breast, lung, and pancreas, alongside protections against infectious diseases including hepatitis, HIV, Ebola, and MERS.
Who are the top competitors of Inovio Pharmaceuticals?
Inovio Pharmaceuticals's top competitors include Moderna, BeiGene and Strand Therapeutics.
What products or services does Inovio Pharmaceuticals offer?
Inovio Pharmaceuticals offers DNA Medicines and CELLECTRA Devices.
Is Inovio Pharmaceuticals publicly traded?
Yes, Inovio Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol INO.
How many acquisitions has Inovio Pharmaceuticals made?
Inovio Pharmaceuticals has made 2 acquisitions, including Bioject, and VGX Pharmaceuticals.
Who are Inovio Pharmaceuticals's investors?
Inovio Pharmaceuticals has 9 investors. Key investors include NIH, Korea Investment Holdings, Gates Foundation, DARPA, and CEPI.
What is Inovio Pharmaceuticals's ticker symbol?
The ticker symbol of Inovio Pharmaceuticals is INO on NASDAQ.